AI and Biomanufacturing

Syllabus: Science and Technology

Source:  TH

Context: The integration of Artificial Intelligence in India’s biomanufacturing sector is accelerating with the rollout of BioE3 Policy and IndiaAI Mission.

About AI and Biomanufacturing:

What is AI in Biomanufacturing?

• It involves using AI tools like machine learning, digital twins, and predictive analytics to automate and optimize biological production processes.
• Key Features:
  • AI models monitor fermentation, pH, temperature, and microbial growth.
  • Digital twins simulate entire bioproduction facilities for testing changes.
  • Predictive systems reduce waste, failure rates, and improve product consistency.

Example: Biocon uses AI for drug screening and quality control.

India’s Current Status in Biomanufacturing:

• India supplies ~60% of global vaccines and is a major hub for generics.
• The specialty chemicals sector is worth ₹2.74 lakh crore and growing.
• AI applications are already deployed in leading firms.

E.g., Wipro’s pharma AI tools, TCS’s AI for clinical trials.

Opportunities for AI in Biotechnology:

• Enhanced Productivity: AI enables real-time monitoring of bioreactors, detecting anomalies like pH or temperature drift before they impact the batch.

E.g. Strand Life Sciences uses AI to streamline biological data analysis for faster diagnostics.

• Lower Cost of Drugs: AI-driven automation reduces dependency on manual oversight and speeds up production cycles, cutting overall manufacturing costs.
• Faster Drug Discovery: AI models can simulate the effect of millions of compounds virtually, reducing lab trials and discovery time.

E.g. Wipro’s AI systems help pharmaceutical firms reduce molecule screening time.

• Rural Health Leap: AI-based tools can provide context-sensitive diagnostics and treatment recommendations in semi-urban/rural areas using region-specific data.
• Export Leadership: AI ensures product consistency and regulatory traceability, enhancing India’s brand as a trusted biomanufacturing exporter.

Government Initiatives:

• BioE3 Policy (2024): Introduces Bio-AI Hubs and biofoundries with funding mechanisms to promote next-gen biotech innovation.
• IndiaAI Mission: Aims at developing explainable, ethical, and inclusive AI models, particularly for healthcare and biotech applications.
• Digital Personal Data Protection Act (2023): Lays down principles of lawful data processing and security but lacks AI-specific safeguards for biomanufacturing.

Challenges:

• Regulatory Gaps: India’s current drug laws don’t account for AI-controlled systems, leading to ambiguity in compliance and approval processes.
• Data Diversity Issues: AI tools trained on urban data may fail to adapt to regional manufacturing variables, risking faulty decisions in diverse settings.
• Safety & Accountability: There’s no institutional mechanism to audit, certify, or red-flag AI-led errors in critical bioproduction lines.
• Intellectual Property (IP): AI-generated innovations challenge traditional IP norms on inventorship, data ownership, and licensing rights.
• Lack of Skilled Workforce: There’s a shortfall in professionals trained in both AI and life sciences, limiting cross-functional innovation.

Measures to be Taken:

• Risk-Based Regulations: Introduce tiered AI regulations similar to the EU’s AI Act or US FDA’s model based on risk-level and context of use.

E.g. Predetermined Change Control Plans allow AI updates under predefined safety checks.

• Data Quality Norms: Mandate inclusion of diverse, representative datasets to train AI for different geographies and plant settings.
• Continuous Oversight: Set up regulatory sandboxes to test and update AI models without disrupting national safety or production norms.
• Cross-Sector Collaboration: Encourage joint task forces between industry, academia, and regulators to co-develop AI benchmarks and best practices.
• IP & Data Licensing Law: Develop clear legal frameworks for AI-generated patents, licensing rights, and access to training datasets in biotech.

Conclusion:

India’s push for AI-driven biomanufacturing holds transformative potential for healthcare and exports. However, ambition must be balanced by adaptive, risk-aware regulation rooted in data integrity and public trust. The future of AI-led biotech leadership will depend on India’s ability to innovate responsibly.

PYQ: